Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $52.53 in the prior trading day, Protagonist Therapeutics Inc (NASDAQ: PTGX) closed at $51.05, down -2.82%. In other words, the price has decreased by -$2.82 from its previous closing price. On the day, 0.78 million shares were traded. PTGX stock price reached its highest trading level at $53.58 during the session, while it also had its lowest trading level at $50.75.
Ratios:
Our goal is to gain a better understanding of PTGX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.14. For the most recent quarter (mrq), Quick Ratio is recorded 12.48 and its Current Ratio is at 12.48. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on December 06, 2024, initiated with a Neutral rating and assigned the stock a target price of $47.
On December 06, 2024, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $62.
On November 05, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $58.Wedbush initiated its Outperform rating on November 05, 2024, with a $58 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 17 ’25 when Waddill William D. sold 4,000 shares for $54.25 per share. The transaction valued at 217,000 led to the insider holds 13,130 shares of the business.
WILLIAM D WADDILL bought 4,000 shares of PTGX for $219,120 on Mar 17 ’25. On Mar 13 ’25, another insider, MOLINA ARTURO MD, who serves as the Chief Medical Officer of the company, sold 30,514 shares for $55.74 each. As a result, the insider received 1,700,850 and left with 83,892 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 3224517120 and an Enterprise Value of 2725620992. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.21 while its Price-to-Book (P/B) ratio in mrq is 4.61. Its current Enterprise Value per Revenue stands at 6.274 whereas that against EBITDA is 10.745.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.35, which has changed by 0.79248595 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $60.60, while it has fallen to a 52-week low of $24.22. The 50-Day Moving Average of the stock is 22.21%, while the 200-Day Moving Average is calculated to be 24.17%.
Shares Statistics:
The stock has traded on average 951.85K shares per day over the past 3-months and 1493980 shares per day over the last 10 days, according to various share statistics. A total of 61.04M shares are outstanding, with a floating share count of 57.88M. Insiders hold about 5.71% of the company’s shares, while institutions hold 99.82% stake in the company. Shares short for PTGX as of 1740700800 were 4865114 with a Short Ratio of 5.11, compared to 1738281600 on 3793117. Therefore, it implies a Short% of Shares Outstanding of 4865114 and a Short% of Float of 8.0299996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Protagonist Therapeutics Inc (PTGX) reflects the collective analysis of 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.05 and low estimates of -$0.75.
Analysts are recommending an EPS of between $0.16 and -$2.42 for the fiscal current year, implying an average EPS of -$1.23. EPS for the following year is -$1.07, with 8.0 analysts recommending between $2.95 and -$3.53.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $225M, while the lowest revenue estimate was $16M, resulting in an average revenue estimate of $98.78M. In the same quarter a year ago, actual revenue was $434.43M
